News – Oxford Sciences Innovation

Updates

Retweet on Twitter Oxford Sciences Innovation Retweeted

Navenio is part of the #DIT100, alongside @cera_care @TektologyHealth and @BeDifrent and in light of #WorldHealthDay, our latest blog provides insights on digital initiatives that can drive improvements in world health. Read here: https://tinyurl.com/ssvp4smc

Reply on Twitter 1379781133072805888 Retweet on Twitter 13797811330728058882 Like on Twitter 13797811330728058884 Twitter 1379781133072805888

Retweet on Twitter Oxford Sciences Innovation Retweeted

Mixergy @MixergyLtd·

8 Apr

Mixergy tanks are 'heat pump ready' 👌

No need to swap your tank in the future should you change to alternative energy sources in the transition to net zero.

The full @FullyChargedShw episode: https://youtu.be/l5q3W0tuLlM

#mixergytank #heatpumps #cleanenergy #renewables #smarthome

Reply on Twitter 1380184270732419075 Retweet on Twitter 13801842707324190754 Like on Twitter 138018427073241907512 Twitter 1380184270732419075

Oxford Sciences Innovation @OSI_Updates·

14 Apr

Quantum Motion's breakthrough could speed up the roll out of quantum computing by decades.

Brilliant article in the @Telegraph by @MORGANMEAKER and @JamesLiamCook.

#oxfordscience #quantum #future

https://www.telegraph.co.uk/technology/2021/04/01/quantum-computing-breakthrough-speed-roll-decades/

Reply on Twitter 1382309620350353411 Retweet on Twitter 13823096203503534113 Like on Twitter 13823096203503534115 Twitter 1382309620350353411

Stay up to date with news from OSI and our portfolio

Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Quantum Computing Breakthrough Shows Blueprint for Scalable Future

Perspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesity

Meet the Founders: Cheerag Shirodaria, CEO and Charalambos Antoniades, CSO, Caristo Diagnostics

Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance

Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Meet Oxford’s Female Founders & CEOs – watch the recorded event!

International Women’s Day: Meet Oxford’s Female Founders

SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor

MoA Tech appoints Virginia Corless as CEO

Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings

Vaccitech appoints two independent board directors

Genomics Plc completes oversubscribed $30m funding round

PepGen Announces Formation of Scientific Advisory Board

Welcome to the portfolio: T-Cypher Bio

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

£2.5M for intelligent battery technology start up, Brill Power

SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman

OSI UPDATES: WINTER 2021 NEWSLETTER

Professor Jerry Chittenden joins First Light Fusion’s Advisory Board

PepGen appoints James McArthur, Ph.D., as President and Chief Executive Officer

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

First patient receives Vaccitech’s VTP-300 in a Phase 1b/2a clinical trial. An experimental immunotherapy for chronic HBV, a global health problem affecting over 250 million people

Introducing our first Entrepreneur in Residence from Biopharma: Damian Crowther

John McHutchison joins the board of Evox Therapeutics

Perspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the body

Ex-Centrica and BP boss Iain Conn joins Oxford Flow board

OQC lab takes delivery of first Proteox worldwide – a significant milestone to building a quantum-powered future

OQC state-of-the-art quantum laboratory opens

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Ultromics’ first-of-a-kind AI solution to help clinicians diagnose coronary artery disease from echiocardiograms in a matter of minutes approved by the FDA

Bodle Technologies Secures Series A Funding Extension

Perspectum issued CPT® Codes for LiverMultiScan® by the American Medical Association to help Drs diagnose and treat liver disease

Clean nuclear: Oxford start-up 10 years ahead of government targets in race to build fusion plant

LifeArc co-leads £6 million funding in DJS Antibodies

MERRY CHRISTMAS FROM ALL THE TEAM AT OSI

Meet the Founder: Sumi Biswas, CEO of SpyBiotech

PepGen raises $45M in Series A funding, led by RA Capital

HEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millions

Software Ate the World, and Soon It Will Write Itself – Wall Street Journal article by Diffblue

Counterfeit drugs and illegitimate vaccines, both costly and deadly, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford University

Refeyn Closes Series A Funding Round, led by Northpond Ventures

The Backstory: Vaccitech and its role in co-inventing the Oxford COVID-19 vaccine

BREAKTHROUGH FOR OXFORD’S COVID VACCINE, CO-INVENTED BY OSI PORTFOLIO COMPANY VACCITECH

Evox Therapeutics launch strategic collaboration with Oxford University to accelerate development of exosome therapies for rare diseases

Mind Foundry raises an additional $13.6 million in Series A funding led by Aioi Nissay Dowa Insurance

OSI UPDATES: AUTUMN 2020 NEWSLETTER

The Backstory: Base Genomics and their mission to defeat cancer through early diagnosis

Oxford Sciences Innovation announces the sale of Base Genomics to Exact Sciences

Vaccitech expands management team with hires including CMO and CFO

Notice of Annual General Meeting

Fusion energy can be the most cost competitive source of baseload power, at the same level as renewables

Oxford Sciences Innovation appoints Alexis Dormandy as CEO

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

3 portfolio companies win the NHSX AI in Healthcare Award

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Biocentury feature: OSI leverages foundational deal with Oxford to build its life sciences portfolio

Celebrating five years of OSI and Oxford’s history of innovation

Meet the Founder: Ilana Wisby, CEO of Oxford Quantum Circuits

The genome only makes sense in 3D, by Lachlan Mackinnon

Orca Computing raises £2.9m in pre-seed funding for photonics quantum computer

Positive Phase 1 readout of Dr Sarah Gilbert covid vaccine

Cybersecurity in the age of quantum: Our investment in PQShield

Evox announces landmark partnerships with pharma giants Takeda and Eli Lilly

Welcome to the portfolio, Base Genomics!

A royal launch of our Grassroots incubator space!

Uciane Scarlett, our Life Sciences principal, on an inclusive biotech sector

Vaccitech CEO Bill Enright on the Oxford Covid-19 vaccine

Ultromics featured in the Wall Street Journal

Introducing the Scientist in Residence

Quantum Motion raises £8m in an oversubscribed Series A led by Inkef Capital

Vaccitech partners with the University of Oxford and AstraZeneca to develop a Covid-19 vaccine

Huma Health (formerly Medopad) acquires Biobeats to develop their mental health capabilities

Niantic acquires 6D.ai to develop their augmented reality platform

Congratulations OMass! Team raises £27.5m in additional Series A funding

Patrick Pichette to step down from OSI board, Chris Chambers announced as new chair

Latent Logic acquired by Waymo. Congratulations to the team!